Waters完成了对BD的生物科学与诊断解决方案业务的转型收购

summarizeSummary

This 8-K announces the consummation of Waters Corporation's previously disclosed acquisition of BD's Biosciences & Diagnostic Solutions business, a major strategic move that fundamentally reshapes the company. The transaction, structured as a Reverse Morris Trust, involved Waters issuing 38.5 million shares, resulting in former BD shareholders owning approximately 39.2% of the combined entity. To finance a $4.0 billion cash distribution to BD, Waters' new subsidiary, SpinCo, secured a $4.0 billion term loan, which Waters has guaranteed. This significant debt and equity issuance will alter Waters' capital structure and financial leverage. The successful closing of this complex, transformative deal, which has been extensively discussed in prior filings (e.g., shareholder approval on Jan 27, strategic rationale on Jan 13), marks a pivotal moment for the company, positioning it as a global leader in high-volume testing and expanding into high-growth adjacent markets. The appointment of Dr. Claire M. Fraser to the board, with her expertise in genomics and molecular diagnostics, further supports the strategic direction of the newly combined business.

check_boxKey Events

• 收购完成

  Waters完成了对BD的生物科学与诊断解决方案业务的收购，这是一项重塑公司战略重点的创造性交易。

• 股份发行与所有权结构

  沃特斯向前 BD 股东发行了 3.85 亿股普通股，现已合并公司的股东总共持有约 39.2% 的股份，摊薄后。

• 重大债务负担

  SpinCo (现为Waters子公司)获得了4.0亿美元的期限贷款，以用于向BD发放现金分配，Waters进入了父公司保证协议，以承担这些义务。

• 战略重组

  该公司成立了四个新部门：Waters 分析科学，Waters 生物科学，Waters 高级诊断，和 Waters 材料科学，反映其扩大关注领域。

auto_awesomeAnalysis

本8-K公告 Waters Corporation 通过反向莫里斯信托（Reverse Morris Trust）结构的方式，完成了以往披露的与 BD 的 Biosciences & Diagnostic Solutions 业务的收购，标志着公司战略转型的重大举措。该交易涉及 Waters 发行 38.5 亿股股票，导致前 BD 股东持有约 39.2% 的合并实体股份。为了为 BD 提供 400 亿美元现金分红，Waters 的新子公司 SpinCo 获得了 400 亿美元期限贷款，Waters 承诺担保此贷款。该重大债务和股权发行将改变 Waters 的资本结构和财务杠杆。该复杂、具有转型意义的交易的成功完成，标志着公司的重大里程碑，推动 Waters 成为全球高容量测试领导者，并扩大进入高成长邻近市场。公司董事会新成员 Dr. Claire M. Fraser 的任命，凭借其基因组学和分子诊断领域的专业知识，为新合并业务的